Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study

Blood (2022) 140 (Supplement 1): 6623–6626.

https://doi.org/10.1182/blood-2022-157761

Published: 2022

Journal Articles

Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-137089

Published: 2020

Journal Articles

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Blood (2020) 135 (10): 735–742.

https://doi.org/10.1182/blood.2019003127

Published: 2020

Includes: Supplemental data

Journal Articles

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study

Blood (2019) 134 (Supplement_1): 4026.

https://doi.org/10.1182/blood-2019-124116

Published: 2019

Journal Articles

Brentuximab Vedotin Alone and in Combination with Bendamustine As Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: Multicentre Experience of the Polish Lymphoma Research Group (PLRG)

Blood (2018) 132 (Supplement 1): 5375.

https://doi.org/10.1182/blood-2018-99-116610

Published: 2018

Journal Articles

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A+AVD) As Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients with Previously Untreated Stage III or IV Hodgkin Lymphoma (HL): The Phase 3 Echelon-1 Study

Blood (2017) 130 (Supplement 1): 6.

https://doi.org/10.1182/blood.V130.Suppl_1.6.6

Published: 2017

Journal Articles

New mutation in hairy cell leukemia

Tadeusz Robak, Piotr Smolewski

Blood (2015) 126 (8): 930–931.

https://doi.org/10.1182/blood-2015-06-652065

Published: 2015

Journal Articles

Novel target to kill CLL

Tadeusz Robak, Piotr Smolewski

Blood (2015) 125 (2): 211–212.

https://doi.org/10.1182/blood-2014-10-606582

Published: 2015

Journal Articles

Expression of Smad Proteins as a Potential Prognostic Factor in Chronic Lymphocytic Leukemia

Magdalena Witkowska, MD, Barbara Cebula-Obrzut, PhD, Agata Majchrzak, PhD, Aleksandra Medra, PhD, Tadeusz Robak, Prof, Piotr Smolewski, Prof

Blood (2014) 124 (21): 1957.

https://doi.org/10.1182/blood.V124.21.1957.1957

Published: 2014

Journal Articles

A Randomized, Multicenter Study (PALG CLL4/ ML 21283) Of Maintenance Treatment With Rituximab Versus Observation After Induction Treatment With Rituximab, Cladribine, and Cyclophosphamide (RCC) Regimen In Patients With Progressive Chronic Lymphocytic Leukemia: Interim Analysis

Tadeusz Robak, Jerzy Z. Blonski, MD, PhD, Krzysztof Jamroziak, MD, PhD, Aleksander Skotnicki, Professor, Magdalena Piotrowska, MD, Anatoly Uss, Professor, Janusz Kloczko, Professor, Jaroslaw Piszcz, Kazimierz Kuliczkowski, Professor, Tomasz Wrobel, MD PhD, Bozena Katarzyna Budziszewska, MD, PhD, Marta Fidecka, Piotr Smolewski, Professor

Blood (2013) 122 (21): 1640.

https://doi.org/10.1182/blood.V122.21.1640.1640

Published: 2013

Journal Articles

Diverse Impact of Notch-1, Jagged-1 and Dll-1 Expression On Response to Treatment and Relapse Free Survival in Acute Myeloid Leukemia.

Magdalena Czemerska, MD, Agnieszka Pluta, MD, PhD, Anna Szmigielska-Kaplon, MD, PhD, Ewa Wawrzyniak, PhD, Barbara Cebula-Obrzut, PhD, Aleksandra Medra, Piotr Smolewski, MD, PhD, Tadeusz Robak, MD, PhD, Agnieszka Wierzbowska, MD, PhD

Blood (2012) 120 (21): 2520.

https://doi.org/10.1182/blood.V120.21.2520.2520

Published: 2012

Journal Articles

Kinetics and Apoptotic Profile of Circulating Endothelial Cells In Patients Undergoing Autologous Stem Cell Transplantation

Anna Szmigielska-Kaplon, MD, PhD, Krawczynska Anna, MS, PhD, Czemerska Magdalena, MD, Agnieszka Pluta, MD, PhD, Barbara Cebula-Obrzut, MS, PhD, Anna Wolska, MD, Olga Grzybowska-Izydorczyk, MD, PhD, Piotr Smolewski, Tadeusz Robak, MD, PhD, Agnieszka Wierzbowska, MD, PhD

Blood (2011) 118 (21): 2961.

https://doi.org/10.1182/blood.V118.21.2961.2961

Published: 2011

Journal Articles

Pro-Apoptotic Effect of An Anti-CD37 Scfv-Fc Fusion Protein, in Combination with the Anti-CD20 Antibody, Ofatumumab, on Tumor Cells From B-Cell Malignancies

Piotr Smolewski, Robak Pawel, Barbara Cebula-Obrzut, Malgorzata Misiewicz, Aleksandra Jeske, Agata Majchrzak, Scott Stromatt, MD, Tadeusz Robak

Blood (2011) 118 (21): 1662.

https://doi.org/10.1182/blood.V118.21.1662.1662

Published: 2011

Journal Articles

Pro-Apoptotic Activity of Honokiol Analogues in B-Cell Lymphoid Malignancies

Piotr Smolewski, Aleksandra Jeske, Agata Majchrzak, Barbara Cebula, Michael Y Bonner, Jack L Arbiser, Tadeusz Robak

Blood (2011) 118 (21): 1663.

https://doi.org/10.1182/blood.V118.21.1663.1663

Published: 2011

Journal Articles

Antitumor Activity of Amphibian Ribonucleases, Onconase and R-Amhinase, on Tumor Cells From B-Cell Lymphoproliferative Disorders

Piotr Smolewski, Malgorzata Zwoliñska, Barbara Cebula-Obrzut, Agata Majchrzak, Malgorzata Misiewicz, Aleksandra Jeske, Zbigniew Darzynkiewicz, Wojciech Ardelt, Barbara Ardelt, Shailendra K Saxena, Charles Muniz, Tadeusz Robak

Blood (2010) 116 (21): 2842.

https://doi.org/10.1182/blood.V116.21.2842.2842

Published: 2010

Journal Articles

The Prognostic Role of Jagged-1 Protein Expression In Acute Myeloid Leukemia Patients

Agnieszka Wierzbowska, MD, PhD, Agnieszka Pluta, MD, PhD, Konrad Stepka, MD, Magdalena Czemerska, MD, Barbara Cebula-Obrzut, PhD, Anna Krawczynska, PhD, Olga Grzybowska-Izydorczyk, MD, PhD, Piotr Smolewski, MD, PhD, Tadeusz Robak, MD, PhD

Blood (2010) 116 (21): 2726.

https://doi.org/10.1182/blood.V116.21.2726.2726

Published: 2010

Journal Articles

The Role of Inhibitor of Apoptosis Proteins Family Expression In Acute Myeloid Leukemia Patients

Agnieszka Pluta, MD, PhD, Agata Wrzesien-Kus, MD, PhD, Barbara Cebula-Obrzut, PhD, Konrad Stepka, MD, Anna Wolska, MD, Olga Grzybowska-Izydorczyk, MD, PhD, Magdalena Czemerska, MD, Piotr Smolewski, MD, PhD, Tadeusz Robak, MD, PhD, Agnieszka Wierzbowska, MD, PhD

Blood (2010) 116 (21): 2728.

https://doi.org/10.1182/blood.V116.21.2728.2728

Published: 2010

Journal Articles

The Prognostic Role of Smac/DIABLO Protein Expression in Acute Myeloid Leukemia.

Agnieszka Pluta, Agata Wrzesien-Kus, Barbara Cebula, Anna Wolska, Anna Szmigielska-Kaplon, Magdalena Czemerska, Piotr Smolewski, Tadeusz Robak, Agnieszka Wierzbowska

Blood (2009) 114 (22): 2626.

https://doi.org/10.1182/blood.V114.22.2626.2626

Published: 2009

Journal Articles

Expression and Prognostic Significance of the Inhibitor of Apoptosis Protein (IAPs) Family and Its Antagonists in Chronic Lymphocytic Leukemia

Olga Grzybowska-Izydorczyk, Barbara Cebula, Tadeusz Robak, MD, PhD, Piotr Smolewski

Blood (2008) 112 (11): 360.

https://doi.org/10.1182/blood.V112.11.360.360

Published: 2008

Journal Articles

Activity of Anti-Tumor Endoribonucleases, Onconase (ranpirnase) and R-Amphinase in Chronic Lymphocytic Leukemia

Piotr Smolewski, Anna Linke-Szewczyk, Barbara Cebula, Kuslima Shogen, Wojciech Ardelt, Zbigniew Darzynkiewicz, Tadeusz Robak, MD, PhD

Blood (2008) 112 (11): 4205.

https://doi.org/10.1182/blood.V112.11.4205.4205

Published: 2008

NARROW

Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study

Brentuximab Vedotin Alone and in Combination with Bendamustine As Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: Multicentre Experience of the Polish Lymphoma Research Group (PLRG)

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A+AVD) As Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients with Previously Untreated Stage III or IV Hodgkin Lymphoma (HL): The Phase 3 Echelon-1 Study

New mutation in hairy cell leukemia

Novel target to kill CLL

Expression of Smad Proteins as a Potential Prognostic Factor in Chronic Lymphocytic Leukemia

A Randomized, Multicenter Study (PALG CLL4/ ML 21283) Of Maintenance Treatment With Rituximab Versus Observation After Induction Treatment With Rituximab, Cladribine, and Cyclophosphamide (RCC) Regimen In Patients With Progressive Chronic Lymphocytic Leukemia: Interim Analysis

Diverse Impact of Notch-1, Jagged-1 and Dll-1 Expression On Response to Treatment and Relapse Free Survival in Acute Myeloid Leukemia.

Kinetics and Apoptotic Profile of Circulating Endothelial Cells In Patients Undergoing Autologous Stem Cell Transplantation

Pro-Apoptotic Effect of An Anti-CD37 Scfv-Fc Fusion Protein, in Combination with the Anti-CD20 Antibody, Ofatumumab, on Tumor Cells From B-Cell Malignancies

Pro-Apoptotic Activity of Honokiol Analogues in B-Cell Lymphoid Malignancies

Antitumor Activity of Amphibian Ribonucleases, Onconase and R-Amhinase, on Tumor Cells From B-Cell Lymphoproliferative Disorders

The Prognostic Role of Jagged-1 Protein Expression In Acute Myeloid Leukemia Patients

The Role of Inhibitor of Apoptosis Proteins Family Expression In Acute Myeloid Leukemia Patients

The Prognostic Role of Smac/DIABLO Protein Expression in Acute Myeloid Leukemia.

Expression and Prognostic Significance of the Inhibitor of Apoptosis Protein (IAPs) Family and Its Antagonists in Chronic Lymphocytic Leukemia

Activity of Anti-Tumor Endoribonucleases, Onconase (ranpirnase) and R-Amphinase in Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only